Trials / Completed
CompletedNCT00308438
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008
An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
Detailed description
The study is sixteen weeks in duration and there are twelve weeks of once-daily injections into your abdomen or thigh. There are a total of five visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teduglutide (ALX-0600) | 0.1 mg/kg injected subcutaneously daily |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-11-01
- Completion
- 2006-06-01
- First posted
- 2006-03-29
- Last updated
- 2021-05-14
Locations
24 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00308438. Inclusion in this directory is not an endorsement.